Richard Hoetelmans
Overview
Explore the profile of Richard Hoetelmans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ackaert O, Vanhoutte F, Verpoorten N, Buelens A, Lachau-Durand S, Lammens L, et al.
Clin Infect Dis
. 2023 May;
77(6):857-865.
PMID: 37161721
Background: Dengue is a growing global health threat with no specific antiviral drugs available for treatment or prophylaxis. This first-in-human, double-blind, randomized, placebo-controlled study aimed to examine the safety, tolerability,...
2.
Eggers C, Hoetelmans R, Laer S
AIDS
. 2020 Jul;
34(13):1883-1889.
PMID: 32694416
Objective: For the treatment of HIV-1-related brain disease and for the prevention of the brain becoming a viral reservoir, it is important that antiretroviral agents reach sufficient concentrations in the...
3.
Crauwels H, van Heeswijk R, Stevens M, Buelens A, Vanveggel S, Boven K, et al.
AIDS Rev
. 2013 May;
15(2):87-101.
PMID: 23681436
Rilpivirine (TMC278) is a non-nucleoside reverse transcriptase inhibitor approved in combination with other antiretrovirals for the treatment of HIV-1 infection in treatment-naive adults (Edurant(®) 25 mg once daily; Complera(®) [USA]/Eviplera(®)...
4.
Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, Vangeneugden T, et al.
Antimicrob Agents Chemother
. 2010 Jul;
54(10):4440-5.
PMID: 20660678
The drug-drug interaction between rifabutin (RFB) and darunavir/ritonavir (DRV/r) was examined in a randomized, three-way crossover study of HIV-negative healthy volunteers who received DRV/r 600/100 mg twice a day (BID)...
5.
Sekar V, Tomaka F, Lefebvre E, De Pauw M, Vangeneugden T, van den Brink W, et al.
J Clin Pharmacol
. 2010 Apr;
51(2):271-8.
PMID: 20421512
No abstract available.
6.
Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, et al.
AIDS
. 2007 Jun;
21(11):1449-55.
PMID: 17589191
Background: Cumulative antiretroviral exposure can result in multiclass HIV drug resistance. Experimental antiretroviral agents offer limited therapeutic benefit as resistance quickly develops after their introduction as a sole new agent....
7.
Goebel F, Yakovlev A, Pozniak A, Vinogradova E, Boogaerts G, Hoetelmans R, et al.
AIDS
. 2006 Aug;
20(13):1721-6.
PMID: 16931936
Objective: To evaluate antiviral activity, pharmacokinetics, tolerability and safety of TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI), when given as a 25, 50, 100 or 150 mg once-daily dose for...
8.
Sproat M, Pozniak A, Peeters M, Winters B, Hoetelmans R, Graham N, et al.
Antivir Ther
. 2005 May;
10(2):357-61.
PMID: 15865231
Background: In vitro phenotypic resistance studies suggest that the presence of the M184V mutation leads to a reduction in HIV-1 susceptibility to didanosine (ddl). The relevance of this to clinical...
9.
Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, et al.
Antivir Ther
. 2004 Oct;
9(4):537-43.
PMID: 15456085
Objective: To investigate the normalized inhibitory quotient (NIQ) of lopinavir (LPV) as a predictor of 48-week virological responses to a lopinavir/ritonavir (LPV/RTV)-containing regimen in highly treatment-experienced patients. Design: We calculated...
10.
Antinori A, Cozzi-Lepri A, Ammassari A, Trotta M, Nauwelaers D, Hoetelmans R, et al.
Antivir Ther
. 2004 May;
9(2):291-6.
PMID: 15134192
We studied the predictive value of self-reported adherence and plasma drug concentrations on virological rebound to HAART. Among 238 participants in the AdICoNA study who had viral load < or...